Bogomil Voykov
Bogomil Voykov has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Deshka Doycheva
A Centre for Ophthalmology , University Hospital Tuebingen , Tuebingen , Germany
5 shared publications- Emil Nasyrov
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany
4 shared publications - Martin Alexander Leitritz
Department für Augenheilkunde, Universitäts-Augenklinik, Tübingen
4 shared publications Antony William
A Centre for Ophthalmology , University Hospital Tuebingen , Tuebingen , Germany
3 shared publicationsChristoph Deuter
A Centre for Ophthalmology , University Hospital Tuebingen , Tuebingen , Germany
3 shared publicationsSpyridon Dimopoulos
A Centre for Ophthalmology , University Hospital Tuebingen , Tuebingen , Germany
3 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
Preserflo MicroShunt Outcomes in Rare and Refractory Glaucoma Entities Compared with Matched Primary Open-Angle Glaucoma Controls: A Retrospective Exploratory Study
Purpose: To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in rare and refractory glaucoma entities (RRG) in comparison with primary open-angle glaucoma (POAG). Patients and Methods: In this retrospective exploratory study, the primary outcome was the complete 1-year success rate (≥ 20% reduction in IOP from baseline and ≤ 18 mmHg with no medication use). Kaplan–Meier estimates were compared between RRG and POAG (matched 1:1) using the log-rank test. Exploratory sub-analyses were performed for each RRG subgroup. The secondary outcomes included bleb revision and complication rates. Results: Eighty eyes were included in the RRG group (8 primary congenital (PCG), 11 juvenile open-angle (JOAG), 10 aphakic (AG), 14 combined mechanisms (CMG), 17 neovascular (NVG), 13 post-traumatic (TG), 4 oil-induced, 2 steroid-induced glaucoma, and 1 with idiopathically elevated episcleral venous pressure) and matched to 80 eyes with POAG based on baseline characteristics. The 1-year success rates were 56% in the RRG and 71% in the POAG groups (p = 0.0079). Exploratory subgroup analyses revealed significantly lower success in PCG (2/8), TG (8/13) and NVG (8/17). Success rates in the other groups were not significantly different from POAG. Bleb revisions were required significantly more frequently in the RRG group (58% vs 41%). Severe complications were observed in the RRG group, but did not reach significance. Conclusions: While the PMS demonstrated lower efficacy in RRG compared to POAG overall, this difference was primarily attributable to worse outcomes in NVG, TG, and PCG. Success rates in AG, JOAG, and CMG were not significantly different from POAG controls. The frequent need for postoperative bleb revisions, particularly in NVG, PCG, and TG subgroups, represents an important practical consideration. Given the small subgroup sizes and exploratory design, these findings warrant validation in larger, prospective studies.
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
Open AccessPreserflo MicroShunt Outcomes in Rare and Refractory Glaucoma Entities Compared with Matched Primary Open-Angle Glaucoma Controls: A Retrospective Exploratory Study
Purpose: To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in rare and refractory glaucoma entities (RRG) in comparison with primary open-angle glaucoma (POAG). Patients and Methods: In this retrospective exploratory study, the primary outcome was the complete 1-year success rate (≥ 20% reduction in IOP from baseline and ≤ 18 mmHg with no medication use). Kaplan–Meier estimates were compared between RRG and POAG (matched 1:1) using the log-rank test. Exploratory sub-analyses were performed for each RRG subgroup. The secondary outcomes included bleb revision and complication rates. Results: Eighty eyes were included in the RRG group (8 primary congenital (PCG), 11 juvenile open-angle (JOAG), 10 aphakic (AG), 14 combined mechanisms (CMG), 17 neovascular (NVG), 13 post-traumatic (TG), 4 oil-induced, 2 steroid-induced glaucoma, and 1 with idiopathically elevated episcleral venous pressure) and matched to 80 eyes with POAG based on baseline characteristics. The 1-year success rates were 56% in the RRG and 71% in the POAG groups (p = 0.0079). Exploratory subgroup analyses revealed significantly lower success in PCG (2/8), TG (8/13) and NVG (8/17). Success rates in the other groups were not significantly different from POAG. Bleb revisions were required significantly more frequently in the RRG group (58% vs 41%). Severe complications were observed in the RRG group, but did not reach significance. Conclusions: While the PMS demonstrated lower efficacy in RRG compared to POAG overall, this difference was primarily attributable to worse outcomes in NVG, TG, and PCG. Success rates in AG, JOAG, and CMG were not significantly different from POAG controls. The frequent need for postoperative bleb revisions, particularly in NVG, PCG, and TG subgroups, represents an important practical consideration. Given the small subgroup sizes and exploratory design, these findings warrant validation in larger, prospective studies.
- Open Access
- 21 October 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (3) , e239-e250
Incidence, risk factors, and outcomes of numerical hypotony and choroidal effusion following PRESERFLO MicroShunt implantation
Purpose: To evaluate the incidence, outcomes, and risk factors of numerical hypotony (NH) and choroidal effusion (CE) following standalone PRESERFLO MicroShunt (PMS) implantation. Methods: Primary open‐angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) patients with uni‐ or bilateral surgery at a tertiary university hospital were retrospectively evaluated. Kaplan–Meier estimates of first‐operated eyes were used to analyse the cumulative incidence of NH (intraocular pressure [IOP] of <6 mmHg), CE, and CE requiring intervention. Risk factor analyses were performed using generalised linear mixed models on the patient level, including bilateral cases. Results: In total, 370 patients (235 POAG and 135 PXG) and 435 eyes (288 and 147) were included. The PXG group had a significantly higher incidence of NH (83.7% vs. 69.4%) and CE (34.6% vs. 20.6%). Interventions for CE were required significantly more in PXG patients (20.7% vs. 7.4%). The median CE duration was significantly longer in the PXG group (14 days vs. 7 days). The following risk factors were identified: PXG (development of NH, CE, and CE requiring intervention); spherical hyperopic refractive error (CE and CE requiring intervention); male sex and higher age (CE); number of preoperative medications (CE requiring intervention), lower preoperative IOP (NH), and higher postoperative IOP drop (CE). The 6‐month visual outcomes were not influenced by the hypotony criteria, but significantly more eyes treated for CE required subsequent bleb revisions. Conclusion: PXG and hyperopic eyes were at risk for developing postoperative CE requiring intervention. They should be monitored more closely and would benefit from primary intraluminal stenting.
- 21 October 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (3) , e239-e250
Open AccessIncidence, risk factors, and outcomes of numerical hypotony and choroidal effusion following PRESERFLO MicroShunt implantation
Purpose: To evaluate the incidence, outcomes, and risk factors of numerical hypotony (NH) and choroidal effusion (CE) following standalone PRESERFLO MicroShunt (PMS) implantation. Methods: Primary open‐angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) patients with uni‐ or bilateral surgery at a tertiary university hospital were retrospectively evaluated. Kaplan–Meier estimates of first‐operated eyes were used to analyse the cumulative incidence of NH (intraocular pressure [IOP] of <6 mmHg), CE, and CE requiring intervention. Risk factor analyses were performed using generalised linear mixed models on the patient level, including bilateral cases. Results: In total, 370 patients (235 POAG and 135 PXG) and 435 eyes (288 and 147) were included. The PXG group had a significantly higher incidence of NH (83.7% vs. 69.4%) and CE (34.6% vs. 20.6%). Interventions for CE were required significantly more in PXG patients (20.7% vs. 7.4%). The median CE duration was significantly longer in the PXG group (14 days vs. 7 days). The following risk factors were identified: PXG (development of NH, CE, and CE requiring intervention); spherical hyperopic refractive error (CE and CE requiring intervention); male sex and higher age (CE); number of preoperative medications (CE requiring intervention), lower preoperative IOP (NH), and higher postoperative IOP drop (CE). The 6‐month visual outcomes were not influenced by the hypotony criteria, but significantly more eyes treated for CE required subsequent bleb revisions. Conclusion: PXG and hyperopic eyes were at risk for developing postoperative CE requiring intervention. They should be monitored more closely and would benefit from primary intraluminal stenting.
- 10 May 2025
- Published by Springer Nature
- p. 255-268
Wundheilung bei Glaukom
- Open Access
- 22 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 2876
Benefits of Explorative Saccade Training in Patients with Advanced Glaucomatous Visual Field Defects—A Randomized, Placebo-Controlled Study
Purpose: Patients with advanced glaucoma have visual field defects that impair mobility and quality of life (QoL). We aim to determine the effects of exploratory saccade training (EST) in such patients with bilateral overlapping scotomas that affect at least one visual field quadrant. Patients and Methods: This study was approved by the Ethics Committee of the Medical Faculty of the University of Tuebingen, Germany, and was registered in the German Clinical Trials Register (DRKS DRKS00031082, date of approval: 2 February 2023). We randomly assigned 27 patients to two groups, one of which trained with a computer-based EST (group 1). A control group (group 2) first used reading training (rapid serial visual presentation, RSVP, a single-word presentation to minimize eye movements) as placebo training (PRT) in regard to EST, which trains eye movements and, in a later phase, also used EST. Each training method required 6 weeks of home training. Main outcome variables were reaction time (RT) during the EST training sessions, RT during a natural search task (table test), reading speed (RS) during training on the screen, and during reading printed paragraphs aloud. QoL was assessed by a questionnaire. Results: Reaction times during EST and the table test improved significantly, which indicated transfer of the training effect to daily life. RS and QoL were reduced at baseline. Reading training improved RS significantly and reached normal median values. QoL improved significantly in the sub-categories regarding mobility problems in group 1. Patients with inferior field defects were more impaired and improved more than those without inferior field defects. Conclusions: As a supplement to the necessary treatment for glaucoma, EST is an effective home training method for rehabilitation by improving reaction time in daily living tasks for patients with advanced glaucoma. Reading training improved RS while reading from a screen as well as reading printed text.
- 22 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 2876
Open AccessBenefits of Explorative Saccade Training in Patients with Advanced Glaucomatous Visual Field Defects—A Randomized, Placebo-Controlled Study
Purpose: Patients with advanced glaucoma have visual field defects that impair mobility and quality of life (QoL). We aim to determine the effects of exploratory saccade training (EST) in such patients with bilateral overlapping scotomas that affect at least one visual field quadrant. Patients and Methods: This study was approved by the Ethics Committee of the Medical Faculty of the University of Tuebingen, Germany, and was registered in the German Clinical Trials Register (DRKS DRKS00031082, date of approval: 2 February 2023). We randomly assigned 27 patients to two groups, one of which trained with a computer-based EST (group 1). A control group (group 2) first used reading training (rapid serial visual presentation, RSVP, a single-word presentation to minimize eye movements) as placebo training (PRT) in regard to EST, which trains eye movements and, in a later phase, also used EST. Each training method required 6 weeks of home training. Main outcome variables were reaction time (RT) during the EST training sessions, RT during a natural search task (table test), reading speed (RS) during training on the screen, and during reading printed paragraphs aloud. QoL was assessed by a questionnaire. Results: Reaction times during EST and the table test improved significantly, which indicated transfer of the training effect to daily life. RS and QoL were reduced at baseline. Reading training improved RS significantly and reached normal median values. QoL improved significantly in the sub-categories regarding mobility problems in group 1. Patients with inferior field defects were more impaired and improved more than those without inferior field defects. Conclusions: As a supplement to the necessary treatment for glaucoma, EST is an effective home training method for rehabilitation by improving reaction time in daily living tasks for patients with advanced glaucoma. Reading training improved RS while reading from a screen as well as reading printed text.
- Open Access
- 11 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4066
Two-Year Results of XEN Gel Stent Implantation for Pseudoexfoliative Glaucoma in Phakic versus Pseudophakic Eyes
Objectives: To investigate whether phakia affects the outcome of XEN-45 gel stent implantation in the treatment of pseudoexfoliative glaucoma (PXG). Methods: A retrospective, comparative cohort study of 30 phakic and 55 pseudophakic PXG patients who received the XEN-45 gel stent at a tertiary centre. The primary outcome measure was two-year success defined as a ≥20% lowering of intraocular pressure (IOP) and a target IOP of 6–21 mmHg. Success was complete without and qualified irrespective of antiglaucoma medication use. Further glaucoma surgery other than needling was regarded as a failure. The secondary outcome measures included changes in IOP, revision and complication rates. Results: The complete two-year success rates were 70% and 59% in the phakic and pseudophakic groups, respectively (p = 0.75, log-rank test), and the qualified rates were 80% and 72%, respectively (p = 0.89). The median IOP reduction from baseline was 54% in phakic, and 46% in pseudophakic eyes. While needling rates were similar, the incidence of early incisional bleb revisions was significantly higher in the phakic eyes (13% vs. 0% within 3 months; p = 0.0098, chi-square). Increasing after a year, significantly more pseudophakic eyes failed due to secondary glaucoma surgery (16% vs. 0%; p = 0.0191). Conclusions: The XEN-45 gel stent offers equally effective IOP control for both phakic and pseudophakic patients. However, the onset of bleb revisions and the necessity for secondary glaucoma surgery differed significantly between the groups.
- 11 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4066
Open AccessTwo-Year Results of XEN Gel Stent Implantation for Pseudoexfoliative Glaucoma in Phakic versus Pseudophakic Eyes
Objectives: To investigate whether phakia affects the outcome of XEN-45 gel stent implantation in the treatment of pseudoexfoliative glaucoma (PXG). Methods: A retrospective, comparative cohort study of 30 phakic and 55 pseudophakic PXG patients who received the XEN-45 gel stent at a tertiary centre. The primary outcome measure was two-year success defined as a ≥20% lowering of intraocular pressure (IOP) and a target IOP of 6–21 mmHg. Success was complete without and qualified irrespective of antiglaucoma medication use. Further glaucoma surgery other than needling was regarded as a failure. The secondary outcome measures included changes in IOP, revision and complication rates. Results: The complete two-year success rates were 70% and 59% in the phakic and pseudophakic groups, respectively (p = 0.75, log-rank test), and the qualified rates were 80% and 72%, respectively (p = 0.89). The median IOP reduction from baseline was 54% in phakic, and 46% in pseudophakic eyes. While needling rates were similar, the incidence of early incisional bleb revisions was significantly higher in the phakic eyes (13% vs. 0% within 3 months; p = 0.0098, chi-square). Increasing after a year, significantly more pseudophakic eyes failed due to secondary glaucoma surgery (16% vs. 0%; p = 0.0191). Conclusions: The XEN-45 gel stent offers equally effective IOP control for both phakic and pseudophakic patients. However, the onset of bleb revisions and the necessity for secondary glaucoma surgery differed significantly between the groups.
- Open Access
- 7 June 2024
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (1) , 172-180
XEN45 gel stent in the treatment of pigmentary glaucoma: A two-year follow-up
Purpose: To investigate safety and efficacy of the XEN gel stent in patients with pigmentary glaucoma (PG). Methods: A retrospective analysis of 26 eyes of 19 patients with PG undergoing XEN gel stent implantation was performed. Best-corrected visual acuity, intraocular pressure (IOP), and number of antiglaucoma medications were analyzed preoperatively, and at 2 weeks and 3, 6, 12, and 24 months after surgery. Success, needling, and complications were analyzed. Complete success was defined as an IOP reduction of >20% and achieving a target IOP of ≤18, ≤15, or ≤12 mmHg without antiglaucoma medication. Qualified success was indicated if the IOP target was reached with or without medication. Results: Mean IOP decreased significantly from 27.6 ± 14.3 (standard deviation, SD) mmHg to 14.3 ± 4.6 mmHg after one year ( p < 0.001) and 15.1 ± 2.7 mmHg ( p < 0.001) after two years. The median number of hypotensive drugs declined significantly from 4 (range: 3–5) to 0 (0–2) and 0 (0–3) after one and two years, respectively. After two years, complete success with an IOP of ≤18 mmHg and ≤15 mmHg was achieved in 73.1% and 61.5%, respectively. Half of the eyes required needling after a median time of 8 months (0.5–34 months). No sight-threatening complications were observed. Conclusion: The XEN gel stent is a safe and effective surgical treatment option for PG. Needling is an important part of the procedure and should be communicated preoperatively to the patients.
- 7 June 2024
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 35 (1) , 172-180
Open AccessXEN45 gel stent in the treatment of pigmentary glaucoma: A two-year follow-up
Purpose: To investigate safety and efficacy of the XEN gel stent in patients with pigmentary glaucoma (PG). Methods: A retrospective analysis of 26 eyes of 19 patients with PG undergoing XEN gel stent implantation was performed. Best-corrected visual acuity, intraocular pressure (IOP), and number of antiglaucoma medications were analyzed preoperatively, and at 2 weeks and 3, 6, 12, and 24 months after surgery. Success, needling, and complications were analyzed. Complete success was defined as an IOP reduction of >20% and achieving a target IOP of ≤18, ≤15, or ≤12 mmHg without antiglaucoma medication. Qualified success was indicated if the IOP target was reached with or without medication. Results: Mean IOP decreased significantly from 27.6 ± 14.3 (standard deviation, SD) mmHg to 14.3 ± 4.6 mmHg after one year ( p < 0.001) and 15.1 ± 2.7 mmHg ( p < 0.001) after two years. The median number of hypotensive drugs declined significantly from 4 (range: 3–5) to 0 (0–2) and 0 (0–3) after one and two years, respectively. After two years, complete success with an IOP of ≤18 mmHg and ≤15 mmHg was achieved in 73.1% and 61.5%, respectively. Half of the eyes required needling after a median time of 8 months (0.5–34 months). No sight-threatening complications were observed. Conclusion: The XEN gel stent is a safe and effective surgical treatment option for PG. Needling is an important part of the procedure and should be communicated preoperatively to the patients.
- 4 April 2024
- Published by Springer Nature
- p. 1-14
Wundheilung bei Glaukom
- Open Access
- 24 March 2024
- Published by Elsevier in AJO International
- Vol. 1 (1)
Spectacles in the American Civil War 1861–1865
- 24 March 2024
- Published by Elsevier in AJO International
- Vol. 1 (1)
Open AccessSpectacles in the American Civil War 1861–1865
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Ophthalmology
- Vol. 2024 (1) , 3895054
Results of XEN45 Gel Stent Implantation in the Treatment of Primary Open‐Angle Glaucoma Using 5, 10 or 20 μg Mitomycin C: A Pilot Study
Background: No consensus has been reached on the adequate dose of mitomycin C (MMC) in XEN45 gel stent implantation. Lower doses have the potential to reduce MMC‐linked side effects. This study aimed to evaluate treatment efficacy of ab interno XEN45 gel stent in primary open‐angle glaucoma (POAG) with three different MMC doses.Methods: This retrospective single‐centre nonrandomised trail included 54 patients (56 eyes) who underwent XEN45 gel stent implantation for POAG with above‐target intraocular pressure (IOP) under medical therapy. Eyes were grouped according to the received MMC dose: Group 1 (20 μg; n = 21), Group 2 (10 μg; n = 14) and Group 3 (5 μg; n = 21). The primary endpoint was the mean IOP change in the three MMC dose groups after 6, 12 and 24 months. Secondary endpoints included the success rate defined as lowering of baseline IOP ≥ 20% and below a cut‐off IOP set at three different levels: ≤ 18, ≤ 16 and ≤ 14 mmHg (Criteriums 1, 2 and 3), the mean number of ocular hypotensive medications and the frequency of needling procedures.Results: After 24 months, the overall mean (standard error) IOP was significantly reduced from 24.7 (0.9) mmHg to 15.2 (0.7) mmHg (p < 0.0001). The average IOP change (standard error) in MMC dose groups 1, 2 and 3 was −8.6 (2) mmHg, −10.1 (2.1) mmHg and −10.4 (2.8) mmHg. Complete success (Criterium 1) was achieved in 50%, 62% and 43% of the eyes in groups 1, 2 and 3. No statistically significant difference was found within the first 24 months between the three MMC dose groups for IOP change, success rate, number of ocular hypotensive medications and the frequency of needling procedures.Conclusions: XE45 was effective in all three dose groups. As the success rate did not significantly differ between the MMC doses, these results may support the use of the lowest dose.Trial Registration: ClinicalTrials.gov identifier: 559/2016BO2
- 1 January 2024
- Published by Wiley in Journal of Ophthalmology
- Vol. 2024 (1) , 3895054
Open AccessResults of XEN45 Gel Stent Implantation in the Treatment of Primary Open‐Angle Glaucoma Using 5, 10 or 20 μg Mitomycin C: A Pilot Study
Background: No consensus has been reached on the adequate dose of mitomycin C (MMC) in XEN45 gel stent implantation. Lower doses have the potential to reduce MMC‐linked side effects. This study aimed to evaluate treatment efficacy of ab interno XEN45 gel stent in primary open‐angle glaucoma (POAG) with three different MMC doses.Methods: This retrospective single‐centre nonrandomised trail included 54 patients (56 eyes) who underwent XEN45 gel stent implantation for POAG with above‐target intraocular pressure (IOP) under medical therapy. Eyes were grouped according to the received MMC dose: Group 1 (20 μg; n = 21), Group 2 (10 μg; n = 14) and Group 3 (5 μg; n = 21). The primary endpoint was the mean IOP change in the three MMC dose groups after 6, 12 and 24 months. Secondary endpoints included the success rate defined as lowering of baseline IOP ≥ 20% and below a cut‐off IOP set at three different levels: ≤ 18, ≤ 16 and ≤ 14 mmHg (Criteriums 1, 2 and 3), the mean number of ocular hypotensive medications and the frequency of needling procedures.Results: After 24 months, the overall mean (standard error) IOP was significantly reduced from 24.7 (0.9) mmHg to 15.2 (0.7) mmHg (p < 0.0001). The average IOP change (standard error) in MMC dose groups 1, 2 and 3 was −8.6 (2) mmHg, −10.1 (2.1) mmHg and −10.4 (2.8) mmHg. Complete success (Criterium 1) was achieved in 50%, 62% and 43% of the eyes in groups 1, 2 and 3. No statistically significant difference was found within the first 24 months between the three MMC dose groups for IOP change, success rate, number of ocular hypotensive medications and the frequency of needling procedures.Conclusions: XE45 was effective in all three dose groups. As the success rate did not significantly differ between the MMC doses, these results may support the use of the lowest dose.Trial Registration: ClinicalTrials.gov identifier: 559/2016BO2
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 17, 2243-2249
New XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study
Purpose: The XEN gel stent was developed to reduce the risks of filtration surgery by standardizing the outflow of aqueous humor into the subconjunctival space. Recently, a modified version of the XEN63 gel stent was introduced. The goal of this study was to assess its efficacy and safety. Methods: This is a prospective, nonrandomized, observational, consecutive case series study at a single tertiary centre. Patients with open-angle glaucoma with above target intraocular pressure (IOP) despite maximal tolerated medication were included. The primary outcome was a change of median IOP. Secondary outcomes included a change in the number of medications, complete success, needling and complication rates. Success was defined as a lowering of IOP > 20% from baseline and IOP ≤ 14 mmHg. Complete success indicated that the target IOP was reached without medications. Results: Six patients were included. The median IOP decreased from 35.5 mmHg (25.0– 40.0 mmHg) at baseline to 11.5 mmHg (4.0– 15.0 mmHg, p = 0.03), and median IOP-lowering medication was reduced from 4.0 (3.0– 4.0) at baseline to 0 (0– 1.0, p = 0.03) after two years. Five patients (83.0%) had a complete success after two years. Two patients (33.0%) required a needling procedure. Three patients (50.0%) required an intervention due to symptomatic hypotony within the first three weeks postoperatively. Hypotony resolved completely or was asymptomatic after three months. Conclusion: Our study demonstrated a statistically significant reduction in both IOP and number of IOP-lowering medications. Complications were well manageable and had no long-term sequelae.
- 1 August 2023
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 17, 2243-2249
Open AccessNew XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study
Purpose: The XEN gel stent was developed to reduce the risks of filtration surgery by standardizing the outflow of aqueous humor into the subconjunctival space. Recently, a modified version of the XEN63 gel stent was introduced. The goal of this study was to assess its efficacy and safety. Methods: This is a prospective, nonrandomized, observational, consecutive case series study at a single tertiary centre. Patients with open-angle glaucoma with above target intraocular pressure (IOP) despite maximal tolerated medication were included. The primary outcome was a change of median IOP. Secondary outcomes included a change in the number of medications, complete success, needling and complication rates. Success was defined as a lowering of IOP > 20% from baseline and IOP ≤ 14 mmHg. Complete success indicated that the target IOP was reached without medications. Results: Six patients were included. The median IOP decreased from 35.5 mmHg (25.0– 40.0 mmHg) at baseline to 11.5 mmHg (4.0– 15.0 mmHg, p = 0.03), and median IOP-lowering medication was reduced from 4.0 (3.0– 4.0) at baseline to 0 (0– 1.0, p = 0.03) after two years. Five patients (83.0%) had a complete success after two years. Two patients (33.0%) required a needling procedure. Three patients (50.0%) required an intervention due to symptomatic hypotony within the first three weeks postoperatively. Hypotony resolved completely or was asymptomatic after three months. Conclusion: Our study demonstrated a statistically significant reduction in both IOP and number of IOP-lowering medications. Complications were well manageable and had no long-term sequelae.